{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T11:35:11Z","timestamp":1765884911752,"version":"3.48.0"},"reference-count":25,"publisher":"Becaris Publishing Limited","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>\n                    <jats:bold>Aim:<\/jats:bold>\n                    Polycythemia vera (PV), a rare, chronic myeloproliferative neoplasm, that negatively impacts patient outcomes, and optimal therapy remains unclear due to a lack of head-to-head trials. A targeted literature review and feasibility assessment for an indirect comparison of ropeginterferon alfa-2b-njft versus peginterferon alfa-2a or ruxolitinib, using standard of care comprising hydroxyurea (HU) as a common comparator was conducted.\n                    <jats:bold>Materials &amp; methods:<\/jats:bold>\n                    A targeted literature review evaluated clinical comparative evidence for PV treatments published between January 2014 and May 2024 in PubMed and relevant conference abstracts. End points of interest included complete hematologic response, molecular response, allele burden, event-free survival and safety. The feasibility of a network meta-analysis (NMA) was evaluated based on homogeneity of patient populations, treatment regimens and end point definitions.\n                    <jats:bold>Results:<\/jats:bold>\n                    Of 193 PubMed records and 460 conference abstracts screened, 40 records were included, representing evidence from 11 randomized controlled trials and 10 observational studies. Among these, 20 studies formed connected evidence networks for the end points of interest. Substantial heterogeneity across studies precluded a robust NMA: patient populations varied (newly diagnosed, high-risk, low-risk, HU-refractory or -intolerant), complete hematologic response definitions differed (e.g., requirement for absence of disease-related symptoms), molecular response thresholds were inconsistent, follow-up durations varied and definitions of standard of care ranged from almost exclusive use of HU to mixed regimens.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    An NMA for PV treatments was not feasible due to significant clinical and methodological heterogeneity across studies, including differences in patient characteristics, treatments, outcome definitions and follow-up times. These findings highlight the importance of standardized clinical trial designs and outcome definitions to enable robust comparative evidence generation for rare conditions like PV.\n                  <\/jats:p>","DOI":"10.57264\/cer-2025-0142","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T10:27:42Z","timestamp":1764671262000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluating the feasibility of a network meta-analysis comparing treatment options in polycythemia vera"],"prefix":"10.57264","volume":"15","author":[{"given":"Paul","family":"Walden","sequence":"first","affiliation":[{"name":"PharmaEssentia, Burlington, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5656-5025","authenticated-orcid":false,"given":"Noemi","family":"Hummel","sequence":"additional","affiliation":[{"name":"Certara GmbH, L\u00f6rrach, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Kopiec","sequence":"additional","affiliation":[{"name":"Certara, Krakow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuzanna","family":"Maliszewska","sequence":"additional","affiliation":[{"name":"Certara, Krakow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emi","family":"Naslazi","sequence":"additional","affiliation":[{"name":"Certara, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"issue":"2","key":"e_1_3_8_3_2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-018-0054-y","article-title":"The 2016 who classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion","volume":"8","author":"Barbui T","year":"2018","unstructured":"Barbui T, Thiele J, Gisslinger H The 2016 who classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 8(2), 15 (2018).","journal-title":"Blood Cancer J."},{"issue":"13","key":"e_1_3_8_4_2","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1182\/blood-2001-12-0349","article-title":"Polycythemia vera: myths, mechanisms, and management","volume":"100","author":"Spivak JL","year":"2002","unstructured":"Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood 100(13), 4272\u20134290 (2002).","journal-title":"Blood"},{"issue":"12","key":"e_1_3_8_5_2","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/ajh.26008","article-title":"Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management","volume":"95","author":"Tefferi A","year":"2020","unstructured":"Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am. J. Hematol. 95(12), 1599\u20131613 (2020).","journal-title":"Am. J. Hematol."},{"issue":"4","key":"e_1_3_8_6_2","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/17474086.2023.2198698","article-title":"Polycythemia vera: aspects of its current diagnosis and initial treatment","volume":"16","author":"Silver RT","year":"2023","unstructured":"Silver RT, Abu-Zeinah G. Polycythemia vera: aspects of its current diagnosis and initial treatment. Expert Rev. Hematol. 16(4), 253\u2013266 (2023).","journal-title":"Expert Rev. Hematol."},{"issue":"1","key":"e_1_3_8_7_2","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cncr.22365","article-title":"The burden of fatigue and quality of life in myeloproliferative disorders (mpds): an international internet-based survey of 1179 mpd patients","volume":"109","author":"Mesa RA","year":"2007","unstructured":"Mesa RA, Niblack J, Wadleigh M The burden of fatigue and quality of life in myeloproliferative disorders (mpds): an international internet-based survey of 1179 mpd patients. Cancer 109(1), 68\u201376 (2007).","journal-title":"Cancer"},{"issue":"2","key":"e_1_3_8_8_2","doi-asserted-by":"crossref","first-page":"oyaf001","DOI":"10.1093\/oncolo\/oyaf001","article-title":"Resource utilization and inpatient hospitalization costs associated with thromboembolic events among patients with polycythemia vera","volume":"30","author":"Yu J","year":"2025","unstructured":"Yu J, Gayle J, Rosenthal N Resource utilization and inpatient hospitalization costs associated with thromboembolic events among patients with polycythemia vera. Oncologist 30(2), oyaf001 (2025).","journal-title":"Oncologist"},{"issue":"12","key":"e_1_3_8_9_2","doi-asserted-by":"crossref","first-page":"E451","DOI":"10.1002\/ajh.26362","article-title":"Cause-specific mortality following polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the US population, 2001\u20132017","volume":"96","author":"Dores GM","year":"2021","unstructured":"Dores GM, Curtis RE, Linet MS, Morton LM. Cause-specific mortality following polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the US population, 2001\u20132017. Am. J. Hematol. 96(12), E451\u2013E454 (2021).","journal-title":"Am. J. Hematol."},{"issue":"6","key":"e_1_3_8_10_2","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European Leukemianet","volume":"29","author":"Barbui T","year":"2011","unstructured":"Barbui T, Barosi G, Birgegard G Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European Leukemianet. J. Clin. Oncol. 29(6), 761\u2013770 (2011).","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"e_1_3_8_11_2","first-page":"2688","article-title":"Benefit of phlebotomy and low-dose aspirin in the prevention of vascular events in patients with EPOR primary familial polycythemia on the island of New Caledonia","volume":"109","author":"Boulnois L","year":"2024","unstructured":"Boulnois L, Robles M, Maaziz N Benefit of phlebotomy and low-dose aspirin in the prevention of vascular events in patients with EPOR primary familial polycythemia on the island of New Caledonia. Haematologica 109(8), 2688\u20132692 (2024).","journal-title":"Haematologica"},{"key":"e_1_3_8_12_2","unstructured":"NCCN. NCCN Clinical Practice Guidelines in Oncology: myeloproliferative neoplasms. Accessed: 14 October 2025 Version 2.2025. Available from: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1477"},{"issue":"3","key":"e_1_3_8_13_2","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","article-title":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase III trial and its extension study","volume":"7","author":"Gisslinger H","year":"2020","unstructured":"Gisslinger H, Klade C, Georgiev P Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase III trial and its extension study. Lancet Haematol. 7(3), e196\u2013e208 (2020).","journal-title":"Lancet Haematol."},{"issue":"1","key":"e_1_3_8_14_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41408-017-0042-7","article-title":"Polycythemia vera treatment algorithm 2018","volume":"8","author":"Tefferi A","year":"2018","unstructured":"Tefferi A, Vannucchi AM, Barbui T. Polycythemia vera treatment algorithm 2018. Blood Cancer J. 8(1), 3 (2018).","journal-title":"Blood Cancer J."},{"key":"e_1_3_8_15_2","unstructured":"FDA. Besremi (ropeginterferon alfa-2b-njft) injection for subcutaneous use. (Accessed: 14 October 2025). Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761166s007lbl.pdf"},{"issue":"9","key":"e_1_3_8_16_2","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"Jak inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison C","year":"2012","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK Jak inhibition with ruxolitinib versus best available therapy for myelofibrosis. N. Engl. J. Med. 366(9), 787\u2013798 (2012).","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"e_1_3_8_17_2","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek S","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N. Engl. J. Med. 366(9), 799\u2013807 (2012).","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"e_1_3_8_18_2","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41375-020-01020-4","article-title":"Interferon alpha therapy in essential thrombocythemia and polycythemia vera \u2013 a systematic review and meta-analysis","volume":"35","author":"Bewersdorf JP","year":"2021","unstructured":"Bewersdorf JP, Giri S, Wang R Interferon alpha therapy in essential thrombocythemia and polycythemia vera \u2013 a systematic review and meta-analysis. Leukemia 35(6), 1643\u20131660 (2021).","journal-title":"Leukemia"},{"issue":"1","key":"e_1_3_8_19_2","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/bcp.12150","article-title":"Overview of methods for comparing the efficacies of drugs in the absence of head-to-head clinical trial data","volume":"77","author":"Kim H","year":"2014","unstructured":"Kim H, Gurrin L, Ademi Z, Liew D. Overview of methods for comparing the efficacies of drugs in the absence of head-to-head clinical trial data. Br. J. Clin. Pharmacol. 77(1), 116\u2013121 (2014).","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"8","key":"e_1_3_8_20_2","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1002\/sim.7223","article-title":"Combining randomized and non-randomized evidence in network meta-analysis","volume":"36","author":"Efthimiou O","year":"2017","unstructured":"Efthimiou O, Mavridis D, Debray TP Combining randomized and non-randomized evidence in network meta-analysis. Stat. Med. 36(8), 1210\u20131226 (2017).","journal-title":"Stat. Med."},{"issue":"2","key":"e_1_3_8_21_2","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/0272989X17725740","article-title":"Methods for population-adjusted indirect comparisons in health technology appraisal","volume":"38","author":"Phillippo DM","year":"2018","unstructured":"Phillippo DM, Ades AE, Dias S Methods for population-adjusted indirect comparisons in health technology appraisal. Med. Decis. Making 38(2), 200\u2013211 (2018).","journal-title":"Med. Decis. Making"},{"issue":"20","key":"e_1_3_8_22_2","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1182\/bloodadvances.2018021436","article-title":"The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera","volume":"2","author":"Podoltsev NA","year":"2018","unstructured":"Podoltsev NA, Zhu M, Zeidan AM The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera. Blood Adv. 2(20), 2681\u20132690 (2018).","journal-title":"Blood Adv."},{"issue":"23","key":"e_1_3_8_23_2","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1182\/blood-2013-01-478891","article-title":"Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and iwg-mrt consensus project","volume":"121","author":"Barosi G","year":"2013","unstructured":"Barosi G, Mesa R, Finazzi G Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and iwg-mrt consensus project. Blood 121(23), 4778\u20134781 (2013).","journal-title":"Blood"},{"issue":"19","key":"e_1_3_8_24_2","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1182\/blood.2022015680","article-title":"Treatment and clinical endpoints in polycythemia vera: seeking the best obtainable version of the truth","volume":"139","author":"Gotlib J","year":"2022","unstructured":"Gotlib J. Treatment and clinical endpoints in polycythemia vera: seeking the best obtainable version of the truth. Blood 139(19), 2871\u20132881 (2022).","journal-title":"Blood"},{"issue":"6","key":"e_1_3_8_25_2","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ajh.23690","article-title":"How common are myeloproliferative neoplasms? A systematic review and meta-analysis","volume":"89","author":"Titmarsh GJ","year":"2014","unstructured":"Titmarsh GJ, Duncombe AS, McMullin MF How common are myeloproliferative neoplasms? A systematic review and meta-analysis. Am. J. Hematol. 89(6), 581\u2013587 (2014).","journal-title":"Am. J. Hematol."},{"key":"e_1_3_8_26_2","doi-asserted-by":"publisher","DOI":"10.3390\/jmahp12020006"},{"issue":"10","key":"e_1_3_8_27_2","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1182\/bloodadvances.2023012459","article-title":"Cytoreductive therapy in younger adults with polycythemia vera: a meta-analysis of safety and outcomes","volume":"8","author":"Chamseddine RS","year":"2024","unstructured":"Chamseddine RS, Savenkov O, Rana S Cytoreductive therapy in younger adults with polycythemia vera: a meta-analysis of safety and outcomes. Blood Adv. 8(10), 2520\u20132526 (2024).","journal-title":"Blood Adv."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2025-0142","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T11:31:00Z","timestamp":1765884660000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2025-0142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.57264\/cer-2025-0142"],"URL":"https:\/\/doi.org\/10.57264\/cer-2025-0142","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"type":"print","value":"2042-6305"},{"type":"electronic","value":"2042-6313"}],"subject":[],"published":{"date-parts":[[2026,1]]},"article-number":"e250142"}}